Today: 29 June 2026
Browse Category

NYSE:OSCR 3 October 2025 - 4 June 2026

Oscar Health gains after Wells Fargo upgrade

Oscar Health gains after Wells Fargo upgrade

Oscar Health soared 15.5% to $23.68 after Wells Fargo upgraded the stock, citing improved 2026 health-exchange trends despite warning that visibility beyond this year remains low; the move outpaced rivals as traders bet on near-term stability, even as risks from expiring tax credits and policy changes linger.
4 June 2026
·
Oscar Health stock rises in premarket after 2026 revenue outlook; House subpoenas add a fresh risk

Oscar Health stock rises in premarket after 2026 revenue outlook; House subpoenas add a fresh risk

Oscar Health shares rose 3.3% to $12.66 in premarket trading after forecasting 2026 revenue of $18.7–$19.0 billion and operating earnings of $250–$450 million. The company posted a wider Q4 net loss of $353 million and a medical loss ratio of 95.4%. A U.S. House panel subpoenaed Oscar and other insurers over ACA subsidy practices. Oscar also disclosed a new $475 million revolving credit facility.
10 February 2026
·
Oscar Health Stock (OSCR) News Today: ACA Subsidy Cliff, Analyst Price Targets, and 2026 Open Enrollment Signals (Dec. 15, 2025)

Oscar Health Stock (OSCR) News Today: ACA Subsidy Cliff, Analyst Price Targets, and 2026 Open Enrollment Signals (Dec. 15, 2025)

Oscar Health shares traded near $16.63 on December 15, 2025, as the ACA open enrollment deadline coincided with new analyst coverage and policy debate in Washington. Congress is weighing the fate of enhanced ACA premium tax credits set to expire at the end of 2025. KFF projects average subsidized premiums could more than double in 2026 if subsidies lapse. Oscar’s business is heavily exposed to these ACA marketplace shifts.
15 December 2025
·
Oscar Health (OSCR) Stock Today: Fresh Analyst Coverage, Big 2027 Profit Hopes and Policy Risk in Focus

Oscar Health (OSCR) Stock Today: Fresh Analyst Coverage, Big 2027 Profit Hopes and Policy Risk in Focus

Oscar Health shares traded near $15.80 on Thursday after closing at $15.59, down 8% despite broader market gains. Stephens & Co. initiated coverage with an “Equal-Weight” rating and a $17 price target. Analyst targets now range from $11 to $25, with volatility metrics remaining elevated. The stock’s 52-week range is $11.20 to $23.80, and market cap stands at about $4.1 billion.
11 December 2025
·
Oscar Health (OSCR) Stock Soars on Piper Sandler Upgrade and ACA Tailwinds – What to Know on November 26, 2025

Oscar Health (OSCR) Stock Soars on Piper Sandler Upgrade and ACA Tailwinds – What to Know on November 26, 2025

Oscar Health shares jumped 8–9% to about $18.20 by mid-afternoon Wednesday, November 26, 2025, with volume topping 10 million shares. The surge followed a Piper Sandler upgrade to “Overweight” and a new $25 price target, citing Oscar’s margin strategy and earnings potential even if ACA subsidies lapse. Earlier in November, major banks had maintained bearish ratings and lower targets.
26 November 2025
··
Oscar Health (OSCR) Stock Soars on Obamacare Subsidy Hopes as AI-Powered Virtual Care Rewrites Its Growth Story

Oscar Health (OSCR) Stock Soars on Obamacare Subsidy Hopes as AI-Powered Virtual Care Rewrites Its Growth Story

Oscar Health shares rose as much as 20% in premarket trading Monday after reports that the White House may propose a two-year extension of enhanced ACA subsidies, with new eligibility limits. The stock traded at $15.47, up about 15% as of 7:56 a.m. ET, according to RTTNews. Oscar recently reported Q3 revenue up 23% year over year to $2.93 billion and membership above 2 million.
24 November 2025
···
Oscar Health (OSCR) launches 2026 South Florida plans, adds ‘HelloMeno’; stock in focus — Nov. 10, 2025

Oscar Health (OSCR) launches 2026 South Florida plans, adds ‘HelloMeno’; stock in focus — Nov. 10, 2025

Oscar Health announced new individual-market plans for Miami-Dade and four nearby South Florida counties, effective January 1, 2026, with enrollment via HealthCare.gov. The company also introduced HelloMeno, a menopause-focused plan with Elektra Health, available in multiple states for 2026. Managed-care stocks fell after Trump criticized ACA subsidies, pressuring marketplace insurers.
10 November 2025
··
Oscar Health (OSCR) Q3 2025: ~$3.0B Revenue, EPS Beats, 2025 Guidance Reaffirmed; Balance Sheet Simplified via Note Exchange — Nov. 6, 2025

Oscar Health (OSCR) Q3 2025: ~$3.0B Revenue, EPS Beats, 2025 Guidance Reaffirmed; Balance Sheet Simplified via Note Exchange — Nov. 6, 2025

Oscar Health reported Q3 revenue of $2.99 billion, up 23% year-over-year but below analyst estimates. The company posted a net loss of $137.5 million, or –$0.53 per share, beating EPS expectations. Medical loss ratio rose to 88.5%. Oscar exchanged $187.5 million of 2031 notes for about 23.3 million shares and reaffirmed its 2025 outlook.
6 November 2025
··
Oscar Health Stock Skyrockets on AI-Fuelled Growth Plans – Analysts Warn of ACA Risks

Oscar Health Stock Skyrockets on AI-Fuelled Growth Plans – Analysts Warn of ACA Risks

Oscar Health shares jumped 11% to $21.50 on Oct. 3, 2025, and traded near $21.76 on Oct. 14, up roughly 40% year-to-date. The company announced a $410 million convertible debt offering to fund AI initiatives and launched a new employer health plan with Hy-Vee. Q2 revenue rose to about $2.9 billion, but net losses widened to $228 million. Analysts remain bearish, with an average price target near $12.
17 October 2025
··
Oscar Health (OSCR) Stock Surges on Expansion Plans – What Analysts Are Saying

Oscar Health (OSCR) Stock Skyrockets on ACA Hopes and Tech-Driven Growth – Can the Insurtech Finally Turn a Profit?

Oscar Health closed at $22.30 on Oct. 6, 2025, with a market cap near $5.6 billion after surging 42% year-to-date. Q2 revenue rose 29% to $2.86 billion, but the company posted a $228 million net loss as its medical loss ratio jumped to 91.1%. Membership topped 2 million. Wall Street consensus remains “Strong Sell,” with an average 12-month price target of $12.
6 October 2025
·
Oscar Health (OSCR) Stock Surges on Expansion Plans – What Analysts Are Saying

Oscar Health (OSCR) Stock Surges on Expansion Plans – What Analysts Are Saying

Oscar Health shares traded near $19.81 midday Oct. 3, up about 2.8%, with a market cap around $4.9 billion. The company reported Q2 revenue of $2.86 billion and a $228 million net loss, serving about 2 million members, mostly in ACA exchanges. On Sep. 11, Oscar announced a $350 million convertible note offering to fund growth and retire its credit line. Analyst ratings remain cautious, with recent downgrades citing ACA risk.
3 October 2025
·

Stock Market Today

  • Top 10 Most Shorted ASX Stocks and Weekly Market Movers
    June 28, 2026, 11:00 PM EDT. The latest Short Seller Series highlights the 10 most heavily shorted stocks on the Australian Securities Exchange (ASX). This report also tracks significant weekly shifts in short interest, indicating which stocks are attracting more or less bearish bets. Investors often study short interest as it reflects market sentiment, showing which shares traders expect to fall. This update provides insight into the biggest risers and fallers in short positions, helping investors gauge potential market moves and emerging risks.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop